TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8383403
Drug: 50% combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% combination of alcuronium (0.125 mg.kg‐1) and tubocurarine (0.255 mg.kg‐1)
Study: 8383403
Drug: Alcuronium alone
Normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium alone (0.25 mg.kg‐1)
Study: 8383403
Drug: Tubocurarine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine alone (0.51 mg.kg‐1)
Study: 8383403
Drug: 33% combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% combination of alcuronium and tubocurarine
Study: 3549739
Drug: Intra-aortic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic administration of protamine sulphate
Study: 3549739
Drug: Intra-right atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-right atrial administration of protamine sulphate
Study: 21218307
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression
Study: 31347012
Drug: dDAVP (lyophilizate
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP (lyophilizate 120 μg)
Study: 31347012
Drug: New age-
Normalized name: TITANIUM DIOXIDE 66.2 mg in 1 g / OCTINOXATE 25 mg in 1 g TOPICAL CREAM [Anew Age-Transforming Concealer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New age- and weight-based dosing regimen
Study: 29952004
Drug: UTTR1147A (IL-22Fc)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UTTR1147A (IL-22Fc) administered intravenously (i.v.) at doses of 1-120 μg/kg
Study: 29952004
Drug: UTTR1147A (IL-22Fc)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UTTR1147A (IL-22Fc) administered subcutaneously (s.c.) at doses of 3-120 μg/kg
Study: 28086766
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention, consisting of 6 sessions (1 individual and 5 group) offered by a psychologist, in addition to treatment as usual.
Study: 26101366
Drug: 9-valent HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent HPV vaccine (3-dose regimen at day 1, month 2, month 6)
Study: 17065355
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose >150 mg/dl
Study: 17065355
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose <110 mg/dl
Study: 15170708
Drug: Intracoronary abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary abciximab treatment
Study: 15170708
Drug: Usual abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual abciximab administration
Study: 9841947
Drug: Conventional flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional flap surgery (previous treatment)
Study: 9841947
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control patients who underwent conventional treatment alone
Study: 8135881
Drug: Intramuscular glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular glucosamine sulfate 400 mg twice a week for 6 weeks
Study: 26307858
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for chronic neuropathic pain
Study: 23543140
Drug: Silodosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (8 mg/daily for a maximum of 4 weeks)
Study: 23543140
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 L of water daily)
Study: 19436289
Drug: Non-stent treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-stent treatments
Study: 16454836
Drug: Etoricoxib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (60 to 120 mg tablet once a day)
Study: 16454836
Drug: Placebo (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet once a day)
Study: 15039128
Drug: Aggressive pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive pharmacological treatment (using statins, beta-blockers, ACE-inhibitors, and aspirin)
Study: 12604023
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of zafirlukast twice a day
Study: 12604023
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of budesonide twice a day
Study: 12604023
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of zafirlukast twice a day and 400 mg of budesonide twice a day
Study: 8232703
Drug: Conventional supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional supportive treatment
Study: 2446759
Drug: Isoprinosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule A: 5 days every 15 days
Study: 2446759
Drug: Isoprinosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule B: 5 days every 15 days for 2 months, then 5 days every 2 months
Study: 30213617
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=5) received weekly boxes of fruits and vegetables and dietary counseling to increase consumption to 8 to 10 daily servings for 12 weeks.
Study: 14600926
Drug: CK‐MB increase
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK‐MB increase > 50 IU/ml (group 1, n = 9)
Study: 14600926
Drug: CK‐MB levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK‐MB levels </= 50 IU/ml (group 2, n = 27)
Study: 14600926
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (CK‐MB > 50 IU/ml)
Study: 14600926
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (CK‐MB </= 50 IU/ml)
Study: 10831545
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin) with HMG
Study: 10831545
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin) with HMG
Study: 10831545
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists (triptorelin or buserelin) with HMG
Study: 9104522
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg granisetron (approximately 60 micrograms.kg‐1)
Study: 9104522
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg droperidol (approximately 25 micrograms.kg‐1)
Study: 8182634
Drug: Home physiotherapy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home physiotherapy treatment program
Study: 8182634
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previously withheld treatment)
Study: 3372681
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg orally) + Alcohol
Study: 3372681
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg orally) + Placebo
Study: 3372681
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg orally)
Study: 31063475
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) and Sofosbuvir (SOF) therapy
Study: 16405734
Drug: Drip-push (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip-push (4 modules weekly over 10 weeks by email)
Study: 16405734
Drug: Drip-pull (modules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip-pull (modules accessible on website with 4 reminders weekly for 10 weeks)
Study: 12922085
Drug: Full adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full adult dose of tick-borne encephalitis vaccine
Study: 12922085
Drug: Half adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half adult dose of tick-borne encephalitis vaccine
Study: 1832424
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose dose
Study: 18438908
Drug: Cumulative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative prednisone dosage in multiple flares subgroup: 7.9 gm
Study: 18438908
Drug: Cumulative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative prednisone dosage in single flare subgroup: 6.0 gm
Study: 18438908
Drug: Cumulative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative prednisone dosage in remission subgroup: 3.9 gm
Study: 16854754
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose azathioprine (0.6-0.75 mg/kg) and oral PUVA therapy
Study: 16854754
Drug: Oral PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PUVA therapy alone
Study: 15331546
Drug: Gastric inhibitory
Normalized name: Gastric inhibitory peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric inhibitory polypeptide (GIP) infusion (2 pmol. kg(‐1). min(‐1), 60‐115 min)
Study: 11557836
Drug: Lifestyle treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatments
Study: 8427943
Drug: Temocapril HCl
Normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril HCl (0.5 mg)
Study: 8427943
Drug: Temocapril HCl
Normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril HCl (1.0 mg)
Study: 8427943
Drug: Temocapril HCl
Normalized name: temocapril HCl
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril HCl (2.0 mg)
Study: 3326213
Drug: Standard enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteric coated preparation
Study: 20639713
Drug: Muffins containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins containing 4 mg Fe as ferrous fumarate with orange juice (25 mg ascorbic acid)
Study: 20639713
Drug: Muffins containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins containing 4 mg Fe as ferrous fumarate with apple juice (no ascorbic acid)
Study: 18348735
Drug: Narconon drug
Normalized name: Narcogen
DrugBank: Trichloroethylene (DB13323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narconon drug education curriculum
Study: 18348735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received drug education after the six-month follow-up)
Study: 17288232
Drug: Antinicotine vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antinicotine vaccines (TA-NIC, NicVAX, CYT002-NicQb)
Study: 12707149
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 (n = 16) at doses of up to 70 mL x kg(‐1) x d(‐1)
Study: 12707149
Drug: HES 200/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 200/0.5 (n = 15) at doses of up to 33 mL x kg(‐1) x d(‐1) followed by human albumin
Study: 9321529
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (induction treatment)
Study: 9321529
Drug: Chemotherapy (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (daunorubicin plus cytarabine) (induction treatment)
Study: 9321529
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (maintenance treatment)
Study: 9321529
Drug: Chemotherapy (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (maintenance treatment)
Study: 9321529
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (induction and maintenance treatment)
Study: 8416719
Drug: Outpatient chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient chemotherapy
Study: 3546124
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (prostaglandin inhibitor) for 1 week after splintage removal
Study: 14754980
Drug: Chlorpheniramine (first-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (first-generation antihistamine)
Study: 14754980
Drug: Cetirizine (second-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (second-generation antihistamine)
Study: 9379690
Drug: Octreotide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (4 months therapy)
Study: 3022664
Drug: Desipramine-lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine-lithium carbonate or lithium carbonate-tranylcypromine sulfate combination treatment
Study: 31599351
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + treatment as usual (TAU)
Study: 22864399
Drug: Persistence on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistence on the stress-challenge task before initiating buprenorphine treatment
Study: 22864399
Drug: Antidepressant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant and placebo groups
Study: 15854186
Drug: Cophenylcaine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cophenylcaine nasal spray
Study: 12162475
Drug: Film-coated tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets (FCT)
Study: 17851680
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution (AS)
Study: 6411230
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin infusion starting at 2 U/hour for adolescents, 4 U/hour for adults, and 6 U/hour for patients with acromegaly
Study: 30582194
Drug: Media Smart-Targeted
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Media Smart-Targeted (MS-T) program (9-module program released weekly)
Study: 28477269
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires regarding awareness and knowledge of cervical cancer
Study: 28477269
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires regarding attitudes towards cervical cancer screening and prevention
Study: 17426065
Drug: Anti-TNF treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF treatments (etanercept, infliximab, adalimumab) in RCTs
Study: 15115499
Drug: PUVA (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA (twice weekly for 3 months)
Study: 15115499
Drug: ECP (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP (once monthly for 6 months at relapse)
Study: 9149168
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery plus radiotherapy (arm A)
Study: 9149168
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy alone (arm B)
Study: 27914503
Drug: TAVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVR with Edwards SAPIEN 3 Transcatheter Heart Valve plus optimal heart failure therapy (OHFT)
Study: 27914503
Drug: Optimal heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal heart failure therapy (OHFT) alone
Study: 23233021
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg daily)
Study: 16398803
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin (GTN)
Study: 14514130
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LJP 394 weekly for 16 weeks followed by three 12-week treatment cycles of 50 mg LJP 394 weekly
Study: 8991843
Drug: Procedures with
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedures with minimal endometrial injury (e.g., syneciolysis, hysteroscopic proximal tubal catheterisation)
Study: 8991843
Drug: Ablative procedures
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative procedures (e.g., resection of myoma, endometrium ablation, septum resection)
Study: 30195616
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral regimen
Study: 19727956
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral treatment
Study: 26762481
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with or without tirofiban
Study: 17385265
Drug: L-NAME (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (1 mg/kg) administered intravenously over 60 minutes
Study: 17385265
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously over 60 minutes
Study: 11978255
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg once a day for 10 days
Study: 11978255
Drug: amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin 500 mg three times per day for 10 days
Study: 7897786
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention with increased intensity and frequency of visits (visits with primary care physician and psychiatrist) and continued surveillance of adherence to medication regimens.
Study: 2087821
Drug: Anthraquinone containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthraquinone containing laxative
Study: 2087821
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anthraquinone laxative)
Study: 16987710
Drug: No antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiretroviral therapy
Study: 12631652
Drug: Baclofen (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (acute administration for 24 hours)
Study: 12631652
Drug: Baclofen (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (chronic administration for four weeks, 10 mg four times daily)
Study: 12631652
Drug: Placebo (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acute administration for 24 hours)
Study: 12631652
Drug: Placebo (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chronic administration for four weeks)
Study: 9360661
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous iron once weekly
Study: 9360661
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous iron twice weekly
Study: 7505159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of detailed written information and anxiety management training
Study: 26847970
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment alone (control)
Study: 23446198
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (specific medication not mentioned)
Study: 20606083
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg once daily)
Study: 20606083
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus Pazopanib (1,000 mg plus 400 mg once daily or 1,500 mg plus 800 mg once daily)
Study: 15867239
Drug: 17AAG (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17AAG (10 to 395 mg/m2)
Study: 15867239
Drug: 17AAG (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17AAG (10 to 295 mg/m2)
Study: 12362100
Drug: EUBT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUBT with 100 mg of (13)C-urea
Study: 12362100
Drug: EUBT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUBT with 50 mg of (13)C-urea
Study: 12362100
Drug: EUBT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUBT with 25 mg of (13)C-urea
Study: 7838898
Drug: Alprazolam therapy
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam therapy (2-2.5 mg for 30 days)
Study: 1707298
Drug: GM-CSF (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (75, 150, 300, or 600 micrograms protein/day, administered SC twice a day for 5 days)
Study: 31939363
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + Photodynamic therapy (using Indocyanine green)
Study: 19583878
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (50 g daily dose with 70% cocoa containing 750 mg polyphenols)
Study: 19583878
Drug: Tomato extract
Normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato extract (one capsule containing 15 mg lycopene per day)
Study: 21999489
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg)